Asaf  Danziger net worth and biography

Asaf Danziger Biography and Net Worth

CEO of NovoCure
Asaf Danziger has served as Chief Executive Officer of Novocure since 2002 and has been a director of Novocure since 2012.  Mr. Danziger has led the company and the development of TTFields therapy from preclinical testing through regulatory approvals to commercial sales in Europe and the United States.  From 1998 to 2002, Mr. Danziger was Chief Executive Officer of Cybro Medical, a subsidiary of Imagyn Medical Technologies.  Mr. Danziger holds a B.Sc. in material engineering from Ben Gurion University of the Negev, Israel.

What is Asaf Danziger's net worth?

The estimated net worth of Asaf Danziger is at least $257,669.51 as of January 5th, 2023. Mr. Danziger owns 13,583 shares of NovoCure stock worth more than $257,670 as of March 28th. This net worth evaluation does not reflect any other assets that Mr. Danziger may own. Additionally, Mr. Danziger receives a salary of $1,520,000.00 as CEO at NovoCure. Learn More about Asaf Danziger's net worth.

How old is Asaf Danziger?

Mr. Danziger is currently 58 years old. There are 7 older executives and no younger executives at NovoCure. Learn More on Asaf Danziger's age.

What is Asaf Danziger's salary?

As the CEO of NovoCure Limited, Mr. Danziger earns $1,520,000.00 per year. Learn More on Asaf Danziger's salary.

How do I contact Asaf Danziger?

The corporate mailing address for Mr. Danziger and other NovoCure executives is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. NovoCure can also be reached via phone at 441534756700 and via email at investorinfo@novocure.com. Learn More on Asaf Danziger's contact information.

Has Asaf Danziger been buying or selling shares of NovoCure?

Asaf Danziger has not been actively trading shares of NovoCure during the last quarter. Most recently, Asaf Danziger sold 212,500 shares of the business's stock in a transaction on Thursday, January 5th. The shares were sold at an average price of $108.74, for a transaction totalling $23,107,250.00. Following the completion of the sale, the chief executive officer now directly owns 13,583 shares of the company's stock, valued at $1,477,015.42. Learn More on Asaf Danziger's trading history.

Who are NovoCure's active insiders?

NovoCure's insider roster includes Michael Ambrogi (COO), Ely Benaim (Insider), Ashley Cordova (CFO), Asaf Danziger (CEO), William Doyle (Executive Chairman), Wilhelmus Groenhuysen (COO), Jeryl Hilleman (Director), Frank Leonard (Insider), Gabriel Leung (Director), Todd Longsworth (General Counsel), Martin Madden (Director), Mukund Paravasthu (COO), Michael Puri (Insider), Pritesh Shah (Insider), William Vernon (Director), and Uri Weinberg (Insider). Learn More on NovoCure's active insiders.

Are insiders buying or selling shares of NovoCure?

During the last twelve months, insiders at the medical equipment provider sold shares 5 times. They sold a total of 3,220 shares worth more than $61,749.10. The most recent insider tranaction occured on November, 1st when EVP Frank X Leonard sold 598 shares worth more than $9,532.12. Insiders at NovoCure own 6.3% of the company. Learn More about insider trades at NovoCure.

Information on this page was last updated on 11/1/2024.

Asaf Danziger Insider Trading History at NovoCure

Asaf Danziger Buying and Selling Activity at NovoCure

This chart shows Asaf Danziger's buying and selling at NovoCure by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$20M-$10M$0$10M$20MTotal Insider BuyingTotal Insider Selling

NovoCure Company Overview

NovoCure logo
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Read More

Today's Range

Now: $18.97
Low: $18.31
High: $19.06

50 Day Range

MA: $21.87
Low: $18.19
High: $27.02

2 Week Range

Now: $18.97
Low: $11.70
High: $34.13

Volume

490,446 shs

Average Volume

1,191,815 shs

Market Capitalization

$2.09 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63